88305 CPT Code Billing Guide: Documentation and Modifiers

Medicare prices 88305 through the Physician Fee Schedule. For calendar year 2026, the code carries a work RVU of 0.73 and a non-facility total RVU of 2.10. Multiplied by the 2026 conversion factor of $33.4009, the national non-facility global rate lands near $70 before geographic adjustment, based on the CMS 2026 relative value file.

That figure is a national estimate. Actual payment shifts by locality through the geographic practice cost indices (GPCI), so a claim in a high-cost metro pays more than the same claim in a rural county.

How the 2026 fee schedule changed the rate

Two 2026 changes moved the number. First, CMS finalized a negative 2.5 percent adjustment to the work RVUs of roughly 7,700 non-time-based codes, an efficiency adjustment that pulled 88305’s work RVU from 0.75 down to 0.73 (CMS CY 2026 Physician Fee Schedule final rule, issued October 31, 2025; summarized by ACOG). Second, CMS set two conversion factors for 2026: $33.40 for services outside a qualifying Alternative Payment Model and $33.57 for those inside one, roughly a 3.3 percent increase over 2025 (ACOG, 2026).

Small RVU shifts add up at volume. A pathology group reading tens of thousands of Level IV specimens a year feels a two-hundredths RVU cut across every claim.

Facility versus non-facility rates

Where the service happens changes the technical payment. In a facility setting such as a hospital outpatient department, Medicare pays the physician only the professional portion, because the hospital is separately paid for the technical resources. In a non-facility setting such as an independent lab, the same global claim carries the full technical value. The rate cited above (near $70) is the non-facility global amount.

Commercial versus Medicare reimbursement

Commercial payers usually pay more than Medicare for 88305. Reported negotiated amounts commonly run from roughly $84 to more than $240 per specimen, with many markets landing near 200 percent of the Medicare allowable, according to 2026 billing data compiled by Transcure. Rates depend entirely on the contract, so a number from one health system tells you little about another.

Professional and technical components: modifier 26 and modifier TC

88305 splits into two billable parts. The professional component covers the pathologist’s interpretation and signed report. The technical component covers the lab work: grossing, processing, embedding, sectioning, and staining the slides. When one entity performs and bills both, the code is reported global, with no modifier.

For 88305, the global rate splits roughly in half between the two components, with each landing in the mid-$30s nationally in recent fee schedules. Exact component values move each year and by locality.

When to append modifier 26

Append modifier 26 when the pathologist reads slides that another entity prepared. A common setup: a hospital lab grosses and processes the tissue, then an outside pathology group interprets it. The group bills 88305-26 for the read, and the hospital bills the technical side. Modifier 26 usage and definition did not change for 2026, per the CY 2026 final rule (MedSole RCM, February 2026).

When to append modifier TC

Append modifier TC when your lab prepares the slides but a separate physician interprets them. Independent diagnostic labs and facilities that own the histology equipment bill 88305-TC for the technical work.

One line to remember. Do not report modifier 26 and modifier TC on the same claim line for the same specimen. If a single entity performs both, bill the global code instead of stacking both modifiers (Coding Ahead, January 2026).

A billing example

A gastroenterologist takes four separately labeled colon biopsies. The tissue goes to an independent lab that grosses, processes, and stains the slides, then a contracted pathologist reads them off-site.

• The lab bills 88305-TC, four units, for the technical work.
• The pathologist bills 88305-26, four units, for the interpretation and report.
• Neither bills the global code, because the work was split between two parties.

The Medicare prostate biopsy exception (G0416)

This is where many prostate claims fall apart. Since January 1, 2015, Medicare does not accept 88305 for prostate needle biopsy. It requires HCPCS code G0416, defined as surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, any number of specimens.

The change ended per-core unit stacking. Under the old rule, a saturation biopsy of a dozen cores could generate a dozen units of 88305. CMS replaced the earlier saturation codes (G0416 through G0419) with a single G0416 that pays once per case, regardless of how many cores arrive (APS Medical Billing).

Commercial payers historically kept accepting 88305 per specimen for prostate, subject to unit caps and contract terms. That gap is narrowing. Aetna, for example, began requiring G0416 for all prostate needle biopsies effective August 1, 2025, aligning with Medicare (Coding Ahead, January 2026). Check the specific payer policy before you code a prostate case, because Medicare and commercial rules can now point to different codes for the same specimen.

Documentation requirements for CPT 88305

A payable 88305 claim rests on a complete pathology report. The report should include:

• A gross description of the specimen (size, shape, color, consistency, and any abnormality noted during grossing)
• Microscopic findings describing cellular detail and any pathology present
• A final diagnosis tied to those findings
• The specimen source and type, which sets the code level
• The signature and date of the interpreting pathologist

Two items draw the most audit attention. Every specimen needs a physician order, and the report needs the pathologist’s authentication. According to a 2025 surgical pathology coding review by Coding Ahead, a missing signed order is the leading cause of audit failure on these claims. Labs performing 88305 also need the appropriate CLIA certification, since histopathology is classified as high-complexity testing.

Medical necessity ties it together. The ordering diagnosis has to support sending the tissue for examination, and the report has to show why the work was done.

Common 88305 denials and how to prevent them

Most 88305 denials trace back to a short list of errors:

• Wrong code for a Medicare prostate biopsy. Use G0416, not 88305, for Medicare beneficiaries.
• Exceeding unit caps. Many commercial payers cap gastrointestinal biopsies near 8 units per day and prostate specimens near 16, so higher counts need documentation and, if denied, an appeal.
• Modifier mismatch. Billing the global rate when only the professional or technical work was performed creates over- or underpayments that invite audits.
• Missing order or signature. No signed order or an unsigned report stops the claim.
• Specimen-to-code mismatch. The specimen has to match the Level IV list. A simpler specimen belongs on 88304, a more complex one on 88307 or 88309.
• Bundled ancillary studies. Special stains and immunohistochemistry (codes such as 88312, 88341, and 88342) are separately reportable when medically necessary, not folded into 88305.

Clean claims share a pattern: the right code for the payer, the correct modifier for the billing arrangement, a specimen that matches the level, and a signed report that supports medical necessity.

Key points for billing the 88305 CPT code accurately

The 88305 CPT code reports Level IV surgical pathology, one unit per separately accessioned specimen. In 2026, its national non-facility Medicare rate sits near $70, reflecting a work RVU of 0.73 and the $33.4009 conversion factor. Split the service with modifier 26 for the pathologist’s read and modifier TC for the lab work, never both on one line. Route Medicare prostate needle biopsies to G0416 instead. Back every claim with a signed report, a matching specimen, and documented medical necessity, and most 88305 denials never happen.